2026-05-17T05:52:33Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/126942024-09-27T21:51:54Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19609

00925njm 22002777a 4500 dc Richi, Patricia author Yuste, Jose Enrique author Navío, Teresa author González-Hombrado, Laura author Salido, Marina author Thuissard-Vasallo, Israel author Jiménez-Díaz, Ana author Llorente, Jesús author Cebrián, Laura author Lojo, Leticia author Steiner, Martina author Cobo, Tatiana author Martín, María Dolores author García-Castro, Marta author Castro, Patricia author Muñoz-Fernández, Santiago author 2021-02-28 Patients with different autoimmune inflammatory diseases (AIID) on biological therapy are at risk of pneumococcal disease. Adults with inflammatory arthropathies, connective tissue diseases, psoriasis, or inflammatory bowel disease on biological therapy such as anti-TNFα, rituximab, tocilizumab, abatacept, or anakinra were included in this study. Patients completed a protocol combining the pneumococcal vaccines PCV13 and PPV23. Immune response against pneumococcal serotypes 1, 3, 7F, 14, 19A, and 19F were assessed evaluating functional antibodies by an opsonophagocytosis killing assay (OPKA). In this study, 182 patients with AIID completed the sequential vaccination protocol. Patients on etanercept tended to achieve OPKA titers against a larger number of serotypes than the rest of patients on other biological therapies, while adalimumab was associated to a lower number of serotypes with OPKA titers. Rituximab was not associated with a worse response when compared with the rest of biological agents. Not glucocorticoids, nor synthetic disease-modifying antirheumatic drugs, interfered with the immune response. OPKA titers against serotype 3 which is one of the most prevalent, was obtained in 44% of patients, increasing up to 58% in those on etanercept. Hence, almost 50% of patients on biological therapy achieved functional antibodies after the administration of a complete pneumococcal vaccination protocol. Vaccines (Basel). 2021 Feb 28;9(3):203. 10.3390/vaccines9030203 2076-393X Vaccines 33671007 http://hdl.handle.net/20.500.12105/12694 OPKA titers PCV13 PPV23 anti-TNFα Autoimmune inflammatory diseases Biological therapy Invasive pneumococcal disease Rituximab Tocilizumab Impact of Biological Therapies on the Immune Response after Pneumococcal Vaccination in Patients with Autoimmune Inflammatory Diseases.